Published in final edited form as:

Tetrahedron Lett. 2010 December 29; 51(52): 6852–6855. doi:10.1016/j.tetlet.2010.10.092.

Total synthesis of LL-Z1640-2 utilizing a late-stage intramolecular Nozaki-Hiyama-Kishi reaction

Christopher A. LeClair, Matthew B. Boxer, Craig J. Thomas, and David J. Maloney

NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, USA

Abstract

A total synthesis of LL-Z1640-2 (**2**), a potent and selective kinase inhibitor, has been completed. The key step of the convergent synthesis utilized a late-stage intramolecular Nozaki-Hiyama-Kishi (NHK) reaction to close the macrocycle at the C6'-C7' bond.

Hypothemycin (**1**) and LL-Z1640-2 (also known as C292 and 5-(Z)-7-oxozeaenol) (**2**) (Figure 1) are macrolactones of the resorcylic acid lactone (RAL) class of natural products that have generated substantial interest due to their potent inhibition of select kinases.^{1,2} Both **1** and **2** are produced via the polyketide biosynthetic pathways of several fungal strains and their structures were first reported in 1980 and 1978, respectively.^{3,4} Extensive research on these agents and related *cis*-enone RALs (i.e. radicicol A and L-783277) revealed **2** is a potent inhibitor of TNF α production,⁵ MEK,⁶ and JNK/p38.^{7,8} Furthermore, it has also been recognized that **1** and **2** target select members of the kinome including Erk2, TAK1, and Kit.⁹⁻¹¹ In 2006, Santi and coworkers showed that the *cis*-enone of **1** acted as a Michael acceptor in the presence of select kinases which contain a conserved cysteine residue (Cys166 in Erk2).¹² This key interaction was further corroborated by X-ray crystal structures of hypothemycin (**1**)¹³ and LL-Z1640-2 (**2**)⁹ covalently bound within the ATP binding domain of Erk2 through the Cys residue. There are at least 46 kinases that contain a Cys residue in this hinge region suggesting a high promiscuity of these important natural products across the kinome. Given the detailed structural understanding of the binding mechanism, obtaining rationally designed analogues that limit binding, covalent modification, and inhibition to a selected sub-domain of the kinome are conceivable. Achieving this goal requires efficient and expedient synthetic methods that afford both the natural products and desired analogues. Recently, Winssinger et al. have synthesized a RAL library of hypothemycin, LL-Z-1640-2, and L-783277 analogues to investigate the structure-activity relationship of kinase inhibition.¹⁴

The first total synthesis of LL-Z1640-2 (**2**) was published by Tatsuta¹⁵ in 2001 followed by the Lett¹⁶ and Winssinger¹⁷ groups completing total syntheses of **2** and hypothemycin (**1**). Additionally, Marquez and coworkers have detailed a synthesis establishing the framework needed to complete the total synthesis of **2** via a late-stage ring-closing metathesis reaction,¹⁸ while Hearn et al. recently presented a semisynthetic approach to analogues of **1**.¹⁹

Send proofs to: Dr. Craig J. Thomas craigt@mail.nih.gov NIH Chemical Genomics Center NHGRI, National Institutes of Health 9800 Medical Center Drive Building B, Room 2055 MSC: 3370 Bethesda, MD 20892-3370.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supporting Information **Available:** Experimental procedures and characterization data along with NMR spectra are provided.

Despite the use of different subunits in constructing the carbon framework, all three total syntheses relied upon a macrolactonization to establish the core ring structure.¹⁵⁻¹⁷ Diverging from previous synthetic strategies towards the preparation of LL-Z1640-2 (**2**), we intended to exploit the intramolecular Nozaki-Hiyama-Kishi (NHK) reaction in macrocycle formation at the C6'-C7' bond.^{20,21} Winssinger and coworkers have published several convergent strategies relying on three principle subunits (an aryl selenide, an alkyl iodide (precursor to C1'-C6') and a *cis*-vinyl bromide (precursor to C7'-C10')) that can be coupled in different sequences to form the cyclic scaffold of **1** and **2**.¹⁷ We envisioned a synthetic strategy that, like the Winssinger approach, was modular and allowed insertion of related fragments for rapid library expansion and SAR explorations. Our route to **2** depended on an aryl selenide nucleophile for a precedented^{17a} sequence of alkylation, oxidation and elimination to generate the requisite C6-C1'-C2' *trans*-olefin scaffold (Figure 1). Subsequent Mitsunobu esterification would provide access to an advanced intermediate poised for macrocyclization with the intramolecular NHK reaction. The success of this strategy would allow modified versions of key intermediates **5**, **6**, and **7** to enter a similar synthetic sequence providing advanced SAR explorations around **2** in a rapid manner.

Synthetic elaboration of the aryl selenide **7** is accomplished starting from commercially available 2,4-dimethoxy-6-methylbenzoic acid via known methods (2-(trimethylsilyl)ethyl (TMSE) protection and selenation).^{17a} Alkene **8** was derived in 2-steps from 2-deoxyribose utilizing an established procedure.²² Further elaboration of **8** involved ozonolysis followed by immediate reduction of aldehyde **9** with NaBH₄ to afford the latent primary alcohol **10**, which was ultimately converted to alkyl iodide **6** using Appel conditions (I₂, PPh₃, imid.) (Scheme 1). Synthesis of both the bromo and iodo versions of the *Z*-vinyl halide subunit began from the same silyl protected *R*-homoallylic alcohol **12**.²³ Olefin cross-metathesis with vinyl boronic acid resulted in the desired *E*-vinyl boronate ester **13** in high yield (Scheme 2).²⁴ Using conditions developed by Brown,²⁵ **13** was subjected to Br₂ resulting in formation of a dibromide species in situ. Treatment with NaOMe/MeOH induced elimination and concomitant TBS deprotection providing *Z*-vinyl bromide **5a**. Preparation of *Z*-vinyl iodide **5b**²⁶ required an alternate synthetic approach as vinyl boronic esters subjected to I₂ under equivalent conditions result in retention of configuration yielding the undesired *E*-vinyl iodide.^{25c,d} As such, ozonolysis of **12** and subsequent Wittig olefination of the formed aldehyde **14** using phosphonium methyl iodide provided *Z*-vinyl iodide **15**, which upon silyl deprotection with HF gave **5b** in good yield.

Treatment of aryl selenide **7** with LDA followed by addition of alkyl iodide **6** produced a mixture of alkylation products, which upon stirring with H₂O₂ afforded *trans*-olefin product **16** exclusively and in high yield (Scheme 3). Removal of the TMSE group with TBAF furnished the key carboxylic acid intermediate **4** in excellent yield. The carbon skeleton is completed via Mitsunobu esterification with either vinyl bromide **5a** or vinyl iodide **5b** (yield was unaffected by the halogen). Pivalate deprotection and Dess-Martin oxidation occurred in a straightforward manner giving aldehydes **3a** and **3b** in 90% and 77% yield, respectively.

Initial explorations into the intramolecular NHK reaction to obtain the desired macrocycle **19** utilized vinyl bromide **3a** under various conditions (Table 1). Modifications to solvent system, equivalents of CrCl₂, reaction temperature, and reaction time were all unsuccessful in improving the low yields. During the course of the reaction, the starting material was rapidly consumed in agreement with the literature that oxidative addition of Ni to the substrate can be fast.²⁰ While the formation of a Cr-O bond is the thermodynamic driving force, the formation of product was slow, which is a common occurrence with the intramolecular NHK reaction.²¹ The diminished yields might be attributed to decomposition of the organochromium intermediates despite the tolerance of numerous functional groups to

the reaction conditions. Attempts at further optimization through prolonged reaction times (>48h) and specialized workup (aq. sodium serinate^{21d}) were unsuccessful. Based on this study, the best reaction conditions (entry 3, Table 1) provided the desired macrolactone in a modest 35% yield.

Further efforts at optimizing the yield prompted a halogen switch to vinyl iodide **3b**, which was subjected to the best vinyl bromide reaction conditions (CrCl₂ (10eq), NiCl₂ (5 mol %), DMF). Gratifyingly, the yield of the intramolecular NHK increased to an acceptable 61% with reduced reaction temperature (room temperature) and time (24 h). Exposure to longer reaction times and increased temperatures were ineffective at increasing the yield. The macrocyclization appears to have proceeded in a stereoselective fashion since macrocycle **19** was isolated as a single diastereomer. Previous examples of the intramolecular NHK reaction have demonstrated that proximal stereocenters and variation of the protecting groups can affect stereochemical outcome.²¹ However, we did not investigate this aspect as the subsequent oxidation of the newly formed allylic alcohol renders the diastereoselectivity inconsequential to the synthesis. The ensuing penultimate Dess-Martin oxidation of the allylic alcohol afforded *cis*-enone **20** without incident. Selective deprotection of the ortho methoxy group with simultaneous removal of the acetonide was elicited by subjecting **20** to BCl₃ as previously reported to complete the total synthesis of LL-Z1640-2 (**2**).^{17a}

In summary, this study has demonstrated the utility of an intramolecular Nozaki-Hiyama-Kishi reaction in establishing the macrolactone during the total synthesis of the naturally occurring macrolide LL-Z1640-2 (**2**). The resulting synthetic sequence provides a convergent strategy allowing for rapid exploration of novel analogues of this important natural product.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors thank William Leister for his assistance with normal and reverse phase purification techniques. This research was supported by the Molecular Libraries Initiative of the National Institutes of Health Roadmap for Medical Research, the Intramural Research Program of the National Human Genome Research Institute, and the National Institutes of Health.

References

1. Winssinger N, Barluenga S. *Chem. Commun.* 2007;22–36.
2. Hofmann T, Altmann K-H. *C. R. Chimie.* 2008; 11:1318–1335.
3. a Nair MSR, Carey ST. *Tetrahedron Lett.* 1980; 21:2011–2012. b Nair MSR, Carey ST, James JC. *Tetrahedron.* 1981; 37:2445–2449. (c) corrected structure: Agatsuma T, Takahashi A, Kabuto C, Nozoe S. *Chem. Pharm. Bull.* 1993; 41:373–375.
4. Ellestad GA, Lovell FM, Perkinson NA, Hargreaves RT, McGahren WJ. *J. Org. Chem.* 1978; 43:2339–2343.
5. Rawlins P, Mander T, Sadeghi R, Hill S, Gammon G, Foxwell B, Wrigley S, Moore M. *Int. J. Immunopharmacol.* 1999; 21:799–814. [PubMed: 10606001]
6. Zhao A, Lee SH, Mojena M, Jenkins RG, Patrick DR, Huber HE, Goetz MA, Hensens OD, Zink DL, Vilella D, Dombrowski AW, Lingham RB, Huang L. *J. Antibiotics.* 1999; 52:1086–1094. [PubMed: 10695671]
7. Sugisawa N, Matsuoka M, Okuno T, Igisu H. *Toxicol. Appl. Pharmacol.* 2004; 196:206–214. [PubMed: 15081267]

8. Takehana K, Sato S, Kobayashi T, Maeda T. *Biochem. Biophys. Res. Comm.* 1999; 257:19–23. [PubMed: 10092503]
9. Ohori M, Kinoshita T, Yoshimura S, Varizaya M, Nakajima H, Miyake H. *Biochem. Biophys. Res. Comm.* 2007; 353:633–637. [PubMed: 17194451]
10. Ninomiya-Tsuji J, Kajino T, Ono K, Ohtomo T, Matsumoto M, Shiina M, Mihara M, Tsuchiya M, Matsumoto K. *J. Biol. Chem.* 2003; 278:18485–18490. [PubMed: 12624112]
11. Jensen BM, Beaven MA, Iwaki S, Metcalfe DD, Gilfillan AM. *J. Pharmacol. Exp. Ther.* 2008; 324:128–138. [PubMed: 17925481]
12. Schirmer A, Kennedy J, Murli S, Reid R, Santi DV. *Proc. Nat. Acad. Sci. U.S.A.* 2006; 103:4234–4239.
13. Rastelli G, Rosenfeld R, Reid R, Santi DV. *J. Struct. Biol.* 2008; 164:18–23. [PubMed: 18571434]
14. a Jogireddy R, Dakas P-Y, Valot G, Barluenga S, Winssinger N. *Chem. Eur. J.* 2009; 15:11498–11506. b Jogireddy R, Barluenga S, Winssinger N. *ChemMedChem.* 2010; 5:670–673. [PubMed: 20209566]
15. Tatsuta K, Takano S, Sato T, Nakano S. *Chem. Lett.* 2001:172–173.
16. a Sellès P, Lett R. *Tetrahedron Lett.* 2002; 43:4621–4625. b Sellès P, Lett R. *Tetrahedron Lett.* 2002; 43:4627–4631.
17. a Dakas P-Y, Barluenga S, Totzke F, Zirrgiebel U, Winssinger N. *Angew. Chem. Int. Ed.* 2007; 46:6899–6902. b Dakas P-Y, Jogireddy R, Valot G, Barluenga S, Winssinger N. *Chem. Eur. J.* 2009; 15:11490–11497.
18. Henry N, Robertson MN, Marquez R. *Tetrahedron Lett.* 2007; 48:6088–6091.
19. Hearn BR, Sundermann K, Cannoy J, Santi DV. *ChemMedChem.* 2007; 2:1598–1600. [PubMed: 17691074]
20. For reviews see: a Hargaden G, Guiry PJ. *Adv. Synth. Catal.* 2007; 349:2407–2424. b Fürstner A. *Chem. Rev.* 1999; 99:991–1045. [PubMed: 11848998] c Wessjohann LA, Scheid G. *Synthesis.* 1999:1–36. and references therein.
21. For examples of intramolecular NHK reactions see: a Rowley M, Kishi Y. *Tetrahedron Lett.* 1988; 29:4909–4912. b Schreiber SL, Meyers HV. *J. Am. Chem. Soc.* 1988; 110:5198–5200. c Rowley M, Kishi Y. *J. Am. Chem. Soc.* 1989; 111:2735–2737. d Stamos DP, Sheng XC, Chen SS, Kishi Y. *Tetrahedron Lett.* 1997; 38:6355–6358. e Oddon G, Uguen D. *Tetrahedron Lett.* 1998; 39:1157–1160. f Mi B, Maleczka RE Jr. *Org. Lett.* 2001; 3:1491–1494. [PubMed: 11388849] g Pilli RA, Victor MM. *Tetrahedron Lett.* 2002; 43:2815–2818. h Marshall JA, Eidam PM. *Org. Lett.* 2008; 10:93–96. [PubMed: 18052287]
22. Geng X, Danishefsky SJ. *Org. Lett.* 2004; 6:413–416. [PubMed: 14748606]
23. a Ferrié L, Capdevielle P, Cossy J. *SynLett.* 2005:1933–1935. b BouzBouz S, Cossy J. *Tetrahedron Lett.* 2006; 47:901–904.
24. Morrill C, Grubbs RH. *J. Org. Chem.* 2003; 68:6031–6034. [PubMed: 12868943]
25. a Brown HC, Hamaoka T, Ravindran N. *J. Am. Chem. Soc.* 1973; 95:5786–5788. b Brown HC, Hamaoka T, Ravindran N. *J. Am. Chem. Soc.* 1973; 95:6456–6457. c Brown HC, Subrahmanyam C, Hamaoka T, Ravindran N, Bowman DH, Misumi S, Unni MK, Somayaji V, Bhat NG. *J. Org. Chem.* 1989; 54:6068–6075. d Brown HC, Hamaoka T, Ravindran N, Subrahmanyam C, Somayaji V, Bhat NG. *J. Org. Chem.* 1989; 54:6075–6079.
26. a Conway JC, Urch CJ, Quayle P, Xu J. *SynLett.* 2006:776–780. b Munoz DM, Passey SC, Simpson TJ, Willis CL, Campbell JB, Rosser R. *Aust. J. Org. Chem.* 2004; 57:645–649.

Figure 1.
Structures of hypothemycin (1) and LL-Z1640-2 (2) with retrosynthetic analysis.

Scheme 1.
Synthesis of alkyl iodide subunit **6**.

Scheme 2.
Synthesis of Z-vinyl halides **5a** and **5b**.

Scheme 3.
 Completion of the synthesis of LL-Z1640-2 (**2**).

Table 1

Conditions and results of NHK reaction with **3a**.

NHK Reaction

entry	CrCl ₂ (eq)	NiCl ₂ (mol %)	solvent	temp (°C)	time (h)	yield (%)
1	5	10	DMF	rt	24	15
2	5	10	DMF	50	24	26
3	10	5	DMF	50	48	35
4	10	5	DMF	50	72	34
5	10	5	DMF/4- <i>t</i> BuPy (3:1)	50	48	30
6	10	5	DMSO	50	48	no product
7	10	5	DMSO/4- <i>t</i> BuPy (3:1)	50	48	5
8	10	5	DMSO/DMF (20:1)	50	48	no product
9	10	5	THF/DMF (2:1)	50	48	19
10	10	5	THF/DMF/4- <i>t</i> BuPy (6:3:1)	50	48	12
11	10	5	DME/DMF (6:1)	50	48	10